SciVision Biotech Inc. announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026 on May 14, 2026. For the reporting period from January 1 to March
SciVision Biotech Inc. announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026 on May 14, 2026. For the reporting period from January 1 to March 31, 2026, the company recorded cumulative operating revenue of NT$205,322 thousand and an operating gross profit of NT$145,204 thousand. Net income attributable to owners of the parent was NT$21,956 thousand, resulting in a basic earnings per share of NT$0.29. Total assets at the end of the period were NT$2,751,444 thousand.
FACT BOX
- Source: PR Times
- Category: 業績
FAQ
On what specific date did the Board of Directors of SciVision Biotech Inc. approve the company's Q1 2026 consolidated financial report?
The Board of Directors of SciVision Biotech Inc. officially approved the first quarter consolidated financial report of 2026 on May 14, 2026.
What was the cumulative operating revenue recorded by SciVision Biotech Inc. for the first quarter period ending March 31, 2026?
For the reporting period from January 1 to March 31, 2026, SciVision Biotech Inc. recorded a cumulative operating revenue of NT$205,322 thousand.
What was the operating gross profit reported by SciVision Biotech Inc. during the first quarter of the year 2026?
SciVision Biotech Inc. achieved an operating gross profit of NT$145,204 thousand during the first quarter period from January 1 to March 31, 2026.
How much net income attributable to owners of the parent did SciVision Biotech Inc. report for Q1 2026, and what was the basic earnings per share?
SciVision Biotech Inc. reported a net income attributable to owners of the parent of NT$21,956 thousand, with basic earnings per share at NT$0.29.
What was the total value of assets held by SciVision Biotech Inc. at the end of the first quarter reporting period on March 31, 2026?
At the end of the first quarter period on March 31, 2026, the total assets of SciVision Biotech Inc. stood at NT$2,751,444 thousand.